Note: Ingredients listed on restricted chemical lists
EC/CAS
9005-25-8
Name of the chemical
Starch
Concentration
1-5
EC/CAS
111-76-2
Name of the chemical
Ethylene glycol monobutyl ether (EGBE)
Concentration
0.5-1.5
EC/CAS
10043-35-3
Name of the chemical
Borsäure Borsäure
Concentration
0.1-1
General Information
Version
9
Revision date
2025-12-19
Product name
EMULSION APRAPOLE A-95
1.2.1 Relevant identified uses
Consumer applications
Manufacturer Name
PPG AP Resinas, SA de CV
Icons in SDS
Company Information
company name
PPG AP Resinas, SA de CV
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H317, H360
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Ingredient(s) with unknown acute toxicity
47.9% (oral), 47.9% (dermal), 49.3% (inhalation)
Signal word
Danger
Hazard statements
May damage fertility or the unborn child.
Precautionary statements
General : Keep out of reach of children. If medical advice is needed, have product container or label at hand.
Prevention
Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves, protective clothing and eye or face protection.
Response
IF exposed or concerned: Get medical advice or attention.
Storage
Store locked up.
Disposal
Dispose of contents and container in accordance with all local, regional, national and international regulations.
Supplemental label elements
Contains isothiazolinones. May cause allergic reaction. Repeated exposure to high vapor concentrations may cause irritation of the respiratory system and permanent brain and nervous system damage. Inhalation of vapor/aerosol concentrations above the recommended exposure limits causes headaches, drowsiness and nausea and may lead to unconsciousness or death. Emits toxic fumes when heated.
2.3 Other hazards
None known.
2.1 Classification of the substance or mixture
Percentage of the mixture consisting of ingredient(s) of unknown acute toxicity: 47.9% (oral), 47.9% (dermal), 49.3% (inhalation)
